临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2014年
4期
88-91
,共4页
储文革%胡凤领%刘翔宇%邱睿%梁涛%伍帮荣
儲文革%鬍鳳領%劉翔宇%邱睿%樑濤%伍幫榮
저문혁%호봉령%류상우%구예%량도%오방영
精神分裂症%氨磺必利%利培酮%临床疗效%生活质量%安全性%阳性与阴性症状量表%副反应量表%生活质量综合评定问卷
精神分裂癥%氨磺必利%利培酮%臨床療效%生活質量%安全性%暘性與陰性癥狀量錶%副反應量錶%生活質量綜閤評定問捲
정신분렬증%안광필리%리배동%림상료효%생활질량%안전성%양성여음성증상량표%부반응량표%생활질량종합평정문권
Schizophrenia%amisulpride%risperidone%clinical efficacy%quality of life%safety%PANSS%T ESS%GQOLI-74
目的:探讨氨磺必利对精神分裂症患者临床疗效及生活质量的影响。方法将125例精神分裂症患者随机分为两组,分别口服氨磺必利和利培酮治疗,观察24周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应,生活质量综合评定问卷评定生活质量。结果治疗4周末起两组阳性与阴性症状量表评分均较治疗前显著降低(P<0.01),氨磺必利组治疗8周末起阴性症状因子分显著低于利培酮组( P<0.05或0.01),治疗24周末生活质量综合评定问卷躯体功能、心理功能、社会功能维度分均显著高于利培酮组(P<0.01)。氨磺必利组月经紊乱、血脂异常、血糖异常等不良反应发生率显著低于利培酮组(P<0.05)。结论氨磺必利与利培酮治疗精神分裂症疗效显著且相当,但氨磺必利在改善阴性症状及患者生活质量方面效果更好,安全性更高。
目的:探討氨磺必利對精神分裂癥患者臨床療效及生活質量的影響。方法將125例精神分裂癥患者隨機分為兩組,分彆口服氨磺必利和利培酮治療,觀察24週。採用暘性與陰性癥狀量錶評定臨床療效,副反應量錶評定不良反應,生活質量綜閤評定問捲評定生活質量。結果治療4週末起兩組暘性與陰性癥狀量錶評分均較治療前顯著降低(P<0.01),氨磺必利組治療8週末起陰性癥狀因子分顯著低于利培酮組( P<0.05或0.01),治療24週末生活質量綜閤評定問捲軀體功能、心理功能、社會功能維度分均顯著高于利培酮組(P<0.01)。氨磺必利組月經紊亂、血脂異常、血糖異常等不良反應髮生率顯著低于利培酮組(P<0.05)。結論氨磺必利與利培酮治療精神分裂癥療效顯著且相噹,但氨磺必利在改善陰性癥狀及患者生活質量方麵效果更好,安全性更高。
목적:탐토안광필리대정신분렬증환자림상료효급생활질량적영향。방법장125례정신분렬증환자수궤분위량조,분별구복안광필리화리배동치료,관찰24주。채용양성여음성증상량표평정림상료효,부반응량표평정불량반응,생활질량종합평정문권평정생활질량。결과치료4주말기량조양성여음성증상량표평분균교치료전현저강저(P<0.01),안광필리조치료8주말기음성증상인자분현저저우리배동조( P<0.05혹0.01),치료24주말생활질량종합평정문권구체공능、심리공능、사회공능유도분균현저고우리배동조(P<0.01)。안광필리조월경문란、혈지이상、혈당이상등불량반응발생솔현저저우리배동조(P<0.05)。결론안광필리여리배동치료정신분렬증료효현저차상당,단안광필리재개선음성증상급환자생활질량방면효과경호,안전성경고。
Objective To explore amisulpride’s influence on clinical efficacy and quality of life of schizo-phrenics .Methods A total of 125 chizophrenics were randomly divided into two groups ,they respectively took orally amisulpride and risperidone for 24 weeks .Efficacies were assessed with the Positive and Nega-tive Syndrome Scale (PANSS) ,adverse reactions with the Treatment Emergent Symptom Scale (TESS) and qualities of life with the Generic Quality of Life Inventory-74 (GQOLI-74) .Results Since the end of the 4th week the PANSS scores of both groups lowered more significantly compared with pretreatment (P<0 .01) ,since the end of the 8th week negative symptoms scores were significantly lower (P<0 .05 or 0 .01) and at the end of 24th week physical ,mental and social function score of the GQOLI-74 higher (P<0 .01)in amisulpride than risperidone group .The incidences of menstrual disorder ,abnormal blood lipid and glucose were significantly lower in amisulpride than risperidone group (P< 0 .05) .Conclusion both amisulpride and risperidone have an evident in schizophrenia ,but amisulpride improves negative symptoms and quality of life better and has higher safety .